| Diana Turin, | |
|
17127 Vose St, Lake Balboa, CA 91406-3631 | |
| (310) 770-1153 | |
| Not Available |
| Full Name | Diana Turin |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 17127 Vose St, Lake Balboa, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932951381 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | LMFT145699 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Diana Turin, 17127 Vose St, Lake Balboa, CA 91406-3631 Ph: (310) 770-1153 | Diana Turin, 17127 Vose St, Lake Balboa, CA 91406-3631 Ph: (310) 770-1153 |
News Archive
ITL Group's global operation will be front and centre at the 69th Annual Scientific Meeting and Clinical Lab, from 29 July to 3 August in San Diego, California, marking its first appearance in 15 years.
LouLou Foundation and the Orphan Disease Center (ODC) in the Perelman School of Medicine at the University of Pennsylvania are pleased to announce the award of 11 new research grants into CDKL5 deficiency - a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012.
Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.
› Verified 6 days ago
Allison Brown, PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 6459 Aldea Ave, Lake Balboa, CA 91406 Phone: 818-468-3808 |